These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16859391)

  • 1. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
    Van der Schyf CJ; Gal S; Geldenhuys WJ; Youdim MB
    Expert Opin Investig Drugs; 2006 Aug; 15(8):873-86. PubMed ID: 16859391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.
    Bar-Am O; Amit T; Kupershmidt L; Aluf Y; Mechlovich D; Kabha H; Danovitch L; Zurawski VR; Youdim MB; Weinreb O
    Neurobiol Aging; 2015 Mar; 36(3):1529-42. PubMed ID: 25499799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationally designed multi-targeted agents against neurodegenerative diseases.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Med Chem; 2013; 20(13):1662-72. PubMed ID: 23410161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.
    Pisani L; Catto M; Leonetti F; Nicolotti O; Stefanachi A; Campagna F; Carotti A
    Curr Med Chem; 2011; 18(30):4568-87. PubMed ID: 21864289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.
    Gal S; Fridkin M; Amit T; Zheng H; Youdim MB
    J Neural Transm Suppl; 2006; (70):447-56. PubMed ID: 17017567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
    Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
    Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.
    Brunschweiger A; Koch P; Schlenk M; Rafehi M; Radjainia H; Küppers P; Hinz S; Pineda F; Wiese M; Hockemeyer J; Heer J; Denonne F; Müller CE
    Bioorg Med Chem; 2016 Nov; 24(21):5462-5480. PubMed ID: 27658798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
    Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
    FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.
    Otto R; Penzis R; Gaube F; Adolph O; Föhr KJ; Warncke P; Robaa D; Appenroth D; Fleck C; Enzensperger C; Lehmann J; Winckler T
    J Med Chem; 2015 Aug; 58(16):6710-5. PubMed ID: 26278660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists.
    Castagnoli N; Petzer JP; Steyn S; Castagnoli K; Chen JF; Schwarzschild MA; Van der Schyf CJ
    Neurology; 2003 Dec; 61(11 Suppl 6):S62-8. PubMed ID: 14663013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
    Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.
    Pollak Y; Mechlovich D; Amit T; Bar-Am O; Manov I; Mandel SA; Weinreb O; Meyron-Holtz EG; Iancu TC; Youdim MB
    J Neural Transm (Vienna); 2013 Jan; 120(1):37-48. PubMed ID: 22446839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indanone: a promising scaffold for new drug discovery against neurodegenerative disorders.
    Bansal R; Singh R; Dutta TS; Dar ZA; Bajpai A
    Drug Discov Today; 2024 Aug; 29(8):104063. PubMed ID: 38901670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
    Liu Z; Cai W; Lang M; Yan R; Li Z; Zhang G; Yu P; Wang Y; Sun Y; Zhang Z
    J Mol Neurosci; 2017 Apr; 61(4):498-510. PubMed ID: 28144826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.